Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $42.60.
Several research analysts recently commented on KYMR shares. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 17th. Oppenheimer reiterated an “outperform” rating and issued a $52.00 price target on shares of Kymera Therapeutics in a research report on Wednesday, July 10th. Finally, B. Riley raised their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 9th.
Check Out Our Latest Analysis on Kymera Therapeutics
Kymera Therapeutics Stock Performance
Insider Transactions at Kymera Therapeutics
In other news, Director Joanna Horobin sold 8,500 shares of the company’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the company’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Joanna Horobin sold 8,500 shares of the business’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 502,345 shares of company stock worth $19,279,932. Insiders own 15.82% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kymera Therapeutics by 18.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after purchasing an additional 996,300 shares during the last quarter. BVF Inc. IL increased its holdings in shares of Kymera Therapeutics by 8.9% during the fourth quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock valued at $131,419,000 after acquiring an additional 422,797 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Kymera Therapeutics by 19.2% in the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after purchasing an additional 769,486 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Kymera Therapeutics by 3.0% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,888,888 shares of the company’s stock worth $156,333,000 after purchasing an additional 113,888 shares in the last quarter. Finally, Artal Group S.A. increased its stake in Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after purchasing an additional 496,400 shares in the last quarter.
About Kymera Therapeutics
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Featured Articles
- Five stocks we like better than Kymera Therapeutics
- Using the MarketBeat Dividend Tax Calculator
- From Tokyo to Wall Street: Japan’s Market Impact on U.S. Stocks
- Energy and Oil Stocks Explained
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.